

TAURUS ASSET MANAGEMENT COMPANY LIMITED
 CIN: U67190MH1993PLC073154
 Head Office & Regd Office : 3rd Floor, 301-304, Chandravillas Co-op Premises Society Ltd., AML Centre 2, 8 Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri-East, Mumbai - 400 093 Tel: 022 - 6624 2700
 Email: customercare@taurusmutualfund.com
 A copy of SAI, SIDs and KIMs of the schemes of Taurus Mutual Fund along with application form may be obtained from Fund's website.
www.taurusmutualfund.com

TAURUS Mutual Fund

NOTICE
Hosting of Unaudited Half Yearly Results for the half-year ended 30th September 2024
 Notice is hereby given to the Investors / Unit holders of all the Scheme(s) of Taurus Mutual Fund (the Fund) that in accordance with Regulation 59 of the SEBI (Mutual Funds) Regulations, 1996 read with SEBI (Mutual Funds) (Second Amendment) Regulations 2012 vide SEBI Gazette Notification dated 26th September 2012, the Unaudited Financial Results of all the Schemes of the Fund for the half-year ended September 30, 2024 have been hosted on the fund's website: www.taurusmutualfund.com
 Investors/Unit holders may accordingly view/download the results from the website: <https://www.taurusmutualfund.com/financials>
 For Taurus Asset Management Company Ltd. (Investment Manager for Taurus Mutual Fund)
 Place: Mumbai
 Date: October 25, 2024
 Notice No. 07/2024-2025
 Authorised Signatory
 Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

STEL Holdings Limited
 CIN: L65993KL1990PLC005811 | Regd. Office : 24/1624, Bristow Road, Willingdon Island, Cochin - 682003, Kerala. Email: secretarial@stelholdings.com, Website : www.stelholdings.com

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024
 ₹ in lakhs

PARTICULARS	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		HALF YEAR ENDED		QUARTER ENDED		HALF YEAR ENDED	
	30.09.2024	30.09.2023	30.09.2024	31.03.2024	30.09.2024	30.09.2023	30.09.2024	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1 Total Income from Operations	777.68	416.84	816.41	1,846.41	777.68	416.84	816.41	1,846.41
2 Net Profit / (Loss) from Ordinary activities before Tax	764.06	399.54	776.41	1,774.90	763.87	399.31	776.05	1,773.98
3 Net Profit / (Loss) for the period after Tax	571.72	298.85	580.64	1,328.25	571.53	298.65	580.28	1,327.33
4 Total Comprehensive Income for the period	38,827.39	14,284.87	59,975.10	68,954.62	38,827.20	14,284.67	59,974.74	68,953.70
5 Equity Share Capital	1845.54	1845.54	1845.54	1,845.54	1845.54	1845.54	1845.54	1,845.54
6 Reserves (Excluding Revaluation Reserve)	-	-	2,08,513.10	148,537.99	-	-	2,08,502.77	1,48,528.08
7 (i) Earnings Per Share (before extraordinary items) (of ₹10 each) Basic & Diluted	3.10	1.62	3.15	7.20	3.10	1.62	1.74	7.19
7 (ii) Earnings Per Share (after extraordinary items) (of ₹10 each) Basic & Diluted	3.10	1.62	3.15	7.20	3.10	1.62	1.74	7.19

Notes:-
 1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 25, 2024. The consolidated financial results for the three months and half year ended September 30, 2024 has been compiled by the management in accordance with Ind AS and have not been subjected to audit.
 2. The above is an extract of the detailed format of Quarter and Half year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The detailed financial results are available on the website of the stock exchanges i.e. www.bseindia.com and www.nseindia.com and on the Company's website (www.stelholdings.com)

For and on behalf of the Board of Directors
 Sd/-
 Abraham Ittype
 (DIN 02717344)
 Whole-time Director

Cochin,
 October 25, 2024

MOSCHIP TECHNOLOGIES LIMITED
 CIN: L31909TG1999PLC032184
 Regd Office : 7th Floor, "My Home Twitza", Hyderabad Knowledge City, Hyderabad - 500081. Tel: +91 40 66229292
 email: investorrelations@moschip.com website: <https://moschip.com>

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024
 All amounts in lakhs, except for EPS

Particulars	Quarter ended			Half year ended		
	30-Sep-24 Unaudited	30-Jun-24 Unaudited	30-Sep-23 Unaudited	30-Sep-24 Unaudited	30-Sep-23 Unaudited	31-Mar-24 Audited
Total Income	12,663.14	8,185.19	7,269.73	20,848.33	13,136.69	29,714.97
Net profit for the period / year (before tax and exceptional item)	973.17	410.47	396.09	1,383.64	727.20	1,132.65
Net profit for the period / year (before tax and after exceptional item)	973.17	410.47	396.09	1,383.64	727.20	1,132.65
Net profit for the period / year (after tax and exceptional item)	973.15	398.26	362.57	1,371.41	683.20	988.44
Total comprehensive income for the period / year [comprising profit for the period / year (after tax) and other comprehensive income(after tax)]	896.61	373.76	290.02	1,270.37	610.23	728.22
Equity Share Capital	3,790.90	3,780.25	3,591.23	3,790.90	3,591.23	3,758.77
Other equity (excluding revaluation reserve)	25,518.72	24,183.27	17,001.18	25,518.72	17,001.18	23,184.15
Earnings Per Share (EPS)	Not annualized					Annualized
Basic earnings per share of Rs 2/-each	0.51	0.21	0.20	0.73	0.39	0.55
Diluted earnings per share of Rs2/-each	0.49	0.20	0.19	0.69	0.36	0.52

Key numbers of Standalone Financial Results
 All amounts in lakhs

Particulars	Quarter ended			Half year ended		
	30-Sep-24 Unaudited	30-Jun-24 Unaudited	30-Sep-23 Unaudited	30-Sep-24 Unaudited	30-Sep-23 Unaudited	31-Mar-24 Audited
Total Income	10,601.94	6,278.43	5,398.05	16,880.37	10,277.19	22,605.42
Net profit for the period / year (before tax and after exceptional item)	753.72	347.80	346.38	1,101.52	562.78	621.92
Net profit for the period / year (after tax and exceptional item)	753.72	347.80	346.38	1,101.52	562.78	621.92

1. The above is an extract from the Unaudited Consolidated and Standalone Financial Results for the Quarter and half year ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Standalone Financial Results are available at Company's website www.moschip.com and BSE websites. (scrip code 532407).
 2. The Unaudited Consolidated and Standalone Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules thereunder, other accounting principles generally accepted in India and regulations issued by the Securities and Exchange Board of India ("SEBI").
 3. The Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2024 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 24, 2024. The statutory auditors have carried out review of these Consolidated and Standalone Financial Results and have issued an unmodified report on these results.
 Sd/-
 Srinivasa Kakamanu
 MD & CEO

Place: Hyderabad
 Date: October 24, 2024

glenmark LIFE SCIENCES
Glenmark Life Sciences Limited
 Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeeth, Solapur-413 213, India.
 Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai-400 099, India.
 Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963; Website: www.glenmarklifesciences.com; Email: complianceofficer@glenmarklifesciences.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2024
 ₹ in Millions, unless otherwise stated

Sr. No.	Particulars	Quarter ended			Half Year Ended		
		30 Sep'24	30 Jun'24	30 Sep'23	30 Sep'24	30 Sep'23	31 Mar'24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Income							
Revenue from Operations	5,068.79	5,886.16	5,953.63	10,954.95	11,738.13	22,832.14	
Other Income	85.33	54.93	53.69	140.26	72.20	120.42	
Total Income	5,154.12	5,941.09	6,007.32	11,095.21	11,810.33	22,952.56	
II Expenses							
Cost of Materials Consumed	2,390.77	2,463.55	2,694.04	4,854.32	5,676.17	10,585.80	
Changes in Inventories of Finished Goods and Work-in-Progress	(138.81)	414.34	36.76	275.53	(464.98)	(565.70)	
Employee Benefits Expense	624.39	568.44	667.14	1,192.83	1,148.46	2,581.56	
Finance Costs	3.43	3.53	3.99	6.96	7.95	15.46	
Depreciation and Amortisation Expense	150.93	143.87	131.29	294.80	257.41	534.52	
Other Expenses	848.85	844.98	884.85	1,693.83	1,776.03	3,488.02	
Total Expenses	3,879.56	4,438.71	4,418.07	8,318.27	8,401.04	16,639.66	
III Profit Before Tax (I-II)	1,274.56	1,502.38	1,589.25	2,776.94	3,409.29	6,312.90	
IV Tax Expenses							
Current Tax	302.40	375.17	387.00	677.57	822.99	1,522.14	
Deferred Tax	19.00	12.38	14.88	31.38	44.43	81.88	
Total Tax Expenses	321.40	387.55	401.88	708.95	867.42	1,604.02	
V Profit for the Period / Year (III-IV)	953.16	1,114.83	1,187.37	2,067.99	2,541.87	4,708.88	
VI Other Comprehensive Income (OCI)							
Items that will not be reclassified to profit or loss							
(a) Re-measurement of the post-employment benefit obligation	(7.28)	(2.33)	(25.98)	(9.61)	(26.95)	(72.99)	
(b) Income tax relating to the above	1.91	0.59	6.09	2.50	6.33	18.37	
Total Other Comprehensive Income / (Loss)	(5.37)	(1.74)	(19.89)	(7.11)	(20.62)	(54.62)	
VII Total Comprehensive Income for the Period / Year (V+VI)	947.79	1,113.09	1,167.48	2,060.88	2,521.25	4,654.26	
VIII Earnings per equity share (Face Value of ₹ 2/- each) (Not Annualised except for the year ended 31st March)							
(a) Basic (in ₹)	7.78	9.10	9.69	16.88	20.75	38.43	
(b) Diluted (in ₹)	7.75	9.08	9.69	16.83	20.75	38.38	
IX Paid up Equity Share Capital, Equity Shares of ₹ 2/- each	245.06	245.05	245.05	245.06	245.05	245.05	
X Other Equity excluding Revaluation Reserve						23,078.17	

See accompanying notes to the Financial Results

UNAUDITED BALANCE SHEET AS AT 30TH SEPTEMBER, 2024
 ₹ in Millions

Particulars	As at 30th September 2024 (Unaudited)	As at 31st March 2024 (Audited)
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	8,037.42	7,950.12
Capital Work-in-Progress	1,413.82	1,011.85
Intangible Assets	111.20	100.52
Intangible Assets Under Development	61.50	48.01
Financial Assets		
(i) Investments	0.77	0.77
(ii) Other Financial Assets	110.44	110.30
Income Tax Assets(Net)	75.69	36.72
Other Non-Current Assets	77.17	85.84
Total Non-Current Assets	9,888.01	9,344.13
Current Assets		
Inventories	6,892.03	6,665.91
Financial Assets		
(i) Trade Receivables	7,751.27	7,654.32
(ii) Cash and Cash Equivalents	4,461.17	3,014.14
(iii) Bank Balance other than Cash and Cash Equivalents	1.75	1.80
(iv) Others Financial Assets	839.10	903.68
Other Current Assets	1,015.26	920.14
Total Current Assets	20,960.58	19,159.99
Total Assets	30,848.59	28,504.12
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	245.06	245.05
Other Equity	25,139.74	23,078.17
Total Equity	25,384.80	23,323.22
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(i) Lease Liabilities	133.80	147.61
Provisions	175.92	157.71
Deferred Tax Liabilities (Net)	516.73	487.85
Total Non-Current Liabilities	826.45	793.17
Current Liabilities		
Financial Liabilities		
(i) Lease Liabilities	25.97	23.87
(ii) Trade Payables:		
(a) Total Outstanding dues of Micro & Small Enterprises	213.46	93.82
(b) Total Outstanding dues of Other than Micro & Small Enterprises	3,768.19	3,592.79
(iii) Other Financial Liabilities	383.19	402.68
Other Current Liabilities	108.08	154.23
Provisions	138.45	120.34
Total Current Liabilities	4,637.34	4,387.73
Total Liabilities	5,463.79	5,180.90
Total Equity and Liabilities	30,848.59	28,504.12

UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024
 ₹ in Millions

Particulars	Half Year Ended 30th Sep'24	Half Year Ended 30th Sep'23
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	2,776.94	3,409.29
Adjustments for:		
Loss / (Gain) on Sale / Discard of Property, Plant and Equipment (Net)	11.30	0.09
Depreciation and Amortisation Expense	294.80	257.41
Unrealised foreign exchange (gain) / loss	(2.65)	(10.43)
Provision for Gratuity and Compensated Absence	37.85	39.49
Provision for Doubtful Debts	0.64	20.33
Shared Based Payment Expenses	-	14.05
Interest Income	(125.25)	(74.91)
Finance Costs	6.96	7.95
Operating Profit before Working Capital Changes	3,000.59	3,663.27
Adjustments for Working Capital changes:		
(Increase)/Decrease in Trade Receivables	(97.59)	(27.32)
(Increase)/Decrease in Other Assets	(30.68)	(267.74)
(Increase)/Decrease in Inventories	(226.12)	(653.41)
Increase/(Decrease) in Trade and Other Payables	266.17	108.25
Cash Generated from Operations	2,912.37	2,823.05
Taxes Paid (Net of Refunds)	(716.55)	(660.87)
Net Cash Generated from Operating Activities	2,195.82	2,162.18
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment and Intangible Assets (including Capital Work in Progress)	(856.37)	(627.19)
Interest Received	125.25	74.91
Net Cash used in Investing Activities	(731.12)	(552.28)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from exercise of employee stock options	1.00	-
Principal repayment of Lease Liabilities	(11.71)	(10.71)
Interest payment of Lease Liabilities	(6.96)	(7.95)
Net Cash used in Financing Activities	(17.67)	(18.66)
Net Increase/(Decrease) in Cash and Cash Equivalents	1,447.03	1,591.24
Opening Balance of Cash and Cash Equivalents	3,014.14	2,838.23
Closing Balance of Cash and Cash Equivalents	4,461.17	4,429.47

Notes:
 1. The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
 2. The above Financial Results were reviewed by Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on October 24, 2024. These results have been subjected to limited review by statutory auditor who have issued an unmodified conclusion on the said results.
 3. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM).
 4. As at September 30, 2024, pursuant to Employee Stock Option Plan 2021 8,72,022 options were outstanding, which upon exercise are convertible into equivalent number of equity share.

For Glenmark Life Sciences Limited
 Yasir Rawjee
 Managing Director & CEO

Mumbai, October 24, 2024

ICRA Limited
 Corporate Identity Number (CIN): L74999DL1991PLC042749
 Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001
 Telephone No.: +91-11-23357940; Website: www.icra.in; Email ID: investors@icraindia.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2024
 ₹ in lakhs

S. No.	Particulars	Quarter ended September 30, 2024 (Unaudited)	Six months ended September 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)
1	Total income from operations	12,612.02	24,093.59	10,485.01
2	Net profit / (loss) for the period (before tax, exceptional and/ or extraordinary items)	5,695.26	10,415.94	4

